Portfolio

Engineering platform collagen technology to diagnose fibrosis and advance tissue regeneration science.

Developing smarter formulations of proven drugs, with an early focus on non opioid pain products.

Discovering autoimmune and cancer immunotherapies inspired by the microbiome.

Developing engineered macrophage cell therapies that infiltrate solid tumors, reverse immune suppression, and activate broader anti-tumor immune responses.

Developing small-molecule therapeutics for solid tumors, including renal cancer, colorectal cancer, and melanoma, led by a team with 30 years of combined experience across three prior therapeutic companies.

Developing a first-in-class, brain-penetrant microtubule stabilizer to preserve neuronal structure and address shared neurodegenerative pathologies.

Developing engineered myeloid cell therapies that leverage macrophages’ tumor-homing ability to infiltrate solid tumors and reverse local immune suppression, enabling a broader anti-tumor immune response.

Improving drug discovery success rates by putting a digital cell into every laboratory

AI-guided cardiac screening to bring specialist-level heart care into clinics and homes.

Helping frontline clinicians meet time-critical deadlines with point-of-care tracking and reminder systems.

An AI agent that generates and optimizes biomedical lab protocols for biotech and pharma teams.

Deploying novel polymer-controlled drug delivery devices to treat orthopedic and other surgical bone infections.

Providing noninvasive, point-of-care diagnostics to provide efficicent and economical eosinophilic disease tracking for chronic rhinosinusitis patients.

Developing a first-in-class, oral immunotherapy that inhibits exosome biogenesis to prevent tumor-driven immune evasion and train body to fight cancer.

Evolution Bio is a biotechnology company using its directed evolution technology to optimize drug candidates across a broad range of therapeutic targets.

Eyescreen uses a proprietary ex vivo ERG platform to measure light-evoked electrical responses from post-mortem human retinal tissue, enabling rapid functional testing of drug safety and efficacy in a clinically relevant human model.

Developing the first wearable, real-time biofeedback device to change the paradigm of pelvic floor care.

A research tools company developing automated nanoparticle characterization platforms for drug delivery systems used in oncology, vaccines, and gene therapies.

Develops neural tissue-based computing designed to deliver high-performance AI/ML computation with ultra-low energy consumption.

Building a predictive engine to determine the right treatment for every cancer.

Leash Biosciences uses large-scale automated screening of protein targets against proprietary chemical libraries to discover selective drug candidates and build datasets that enable advanced AI-driven affinity prediction.

Revolutionizing cancer diagnostics by developing non-invasive microRNA-based tests for early cancer detection worldwide, without cold chain management.

Develop a point-of-care, non-invasive, easily accessible method for screening anemia.

Delivering AI-driven diagnostics to the palm of your hand.

Pioneering the battle against chronic kidney disease by exploring groundbreaking biochemical pathways and utilizing advanced computational techniques.

Detecting inflammation in eosinophilic diseases with leading diagnostics and therapies.

A clinical-stage biotech developing evolution-inspired therapies, including elephant-derived p53 and other nature-based mechanisms, to treat cancer and immune diseases.

AI platform that analyzes multi-omics data to identify biomarkers predicting disease and treatment response for diagnostic and companion diagnostic development.

AI Enterprise Solutions for Image-Based Drug Discovery and Beyond.

Rebel Medicine develops long-acting injectable drug delivery systems for controlled release from days to months, including ALX006 for post-surgical pain and a platform for ultra-long-acting therapeutics like GLP-1s.

Developing constrained peptide therapeutics using an integrated AI, mRNA display, and phage display platform to enable large-scale screening and accelerate drug discovery.

Snow Canyon Therapeutics develops small-molecule therapies for neurodegenerative diseases by activating NRF2 to reduce oxidative stress, including programs in ALS.

Our mission is to prevent blindness with the early detection of eye disease, and using the resulting proprietary data set to build a platform for healthcare data analytics.

Providing drug-free noninvasive therapies.

Pioneering single-dose regenerative gene therapies to reverse cellular drivers of osteoarthritis and degenerative disc disease.

SymbioCellTech is a preclinical cellular therapeutics company developing Neo-Islets™, engineered clusters of islet cells and MSCs, to enable insulin-producing cell therapy for diabetes.

AI-powered clinical development to supercharge medical innovation.

Unlocking immune response to guide life changing therapies.

Vira Regen develops noninvasive electroceutical and bioelectric stimulation technologies to activate the body’s natural repair processes for treating injuries and diseases.

Improving outcomes for patients suffering from neurodegenerative disease with next-gen screening diagnostics